Holen Sie sich die Stockscreener-App
8.5871
0.58%
-0.0429
Schlusskurs vom Vortag:
$8.63
Offen:
$8.7
24-Stunden-Volumen:
167.45K
Relative Volume:
0.13
Marktkapitalisierung:
$483.88M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-6.6567
EPS:
-1.29
Netto-Cashflow:
$-33.83M
1W Leistung:
+2.88%
1M Leistung:
+0.00%
6M Leistung:
-25.78%
1J Leistung:
+0.59%
1-Tages-Spanne:
$8.48
$8.86
1-Wochen-Bereich:
$8.21
$8.86
52-Wochen-Spanne:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(321) 939-3416
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Vergleichen Sie ZVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.595 | 485.85M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.00 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.42 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.45 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.41 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-08 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Eingeleitet | Guggenheim | Buy |
| 2024-09-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-24 | Bestätigt | Maxim Group | Buy |
| 2024-04-02 | Bestätigt | Maxim Group | Buy |
| 2024-03-12 | Eingeleitet | William Blair | Outperform |
| 2023-03-17 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Can Zevra Therapeutics Inc. stock withstand economic slowdownJuly 2025 Sentiment & Verified Entry Point Signals - ulpravda.ru
Is Zevra Therapeutics Inc. stock a top pick in earnings seasonQuarterly Profit Summary & Technical Entry and Exit Alerts - ulpravda.ru
What Wall Street predicts for Zevra Therapeutics Inc. stock priceAnalyst Downgrade & Precise Entry and Exit Recommendations - ulpravda.ru
How Zevra Therapeutics Inc. stock benefits from tech adoptionEarnings Risk Summary & Weekly High Potential Alerts - ulpravda.ru
Will Zevra Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Reactions & Consistent Growth Equity Picks - ulpravda.ru
Is Zevra Therapeutics Inc. stock a buy before product launchesWeekly Gains Summary & Weekly Stock Performance Updates - ulpravda.ru
Can Zevra Therapeutics Inc. stock sustain revenue growth2025 Market WrapUp & Intraday High Probability Alerts - ulpravda.ru
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference - The Manila Times
Zevra Therapeutics to Present at J.P. Morgan 44th Annual Healthcare Conference on January 15, 2026 - Quiver Quantitative
Precision Trading with Zevra Therapeutics Inc. (ZVRA) Risk Zones - Stock Traders Daily
Sell Signal: How Zevra Therapeutics Inc stock benefits from tech adoptionLayoff News & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Is Zevra Therapeutics (ZVRA) Using Expanded Access To Quietly Recast Its Rare-Disease Growth Story? - Sahm
TheStreet - thestreet.com
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market - Seeking Alpha
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics announces CFO transition - MSN
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics stock maintains Buy rating at H.C. Wainwright on expanded access deal - Investing.com Nigeria
ZVRA Boosts Distribution for Miplyffa with Uniphar Agreement - GuruFocus
Zevra Therapeutics executes distribution agreement to broaden access to Miplyffa for the treatment of Niemann-Pick disease type C (NPC) - marketscreener.com
Zevra Therapeutics Signs Expanded Miplyffa Distribution Deal With Uniphar - marketscreener.com
Zevra Therapeutics (ZVRA) Expands MIPLYFFA Access with Uniphar A - GuruFocus
Zevra Therapeutics Signs Expanded Access Agreement with Uniphar to Enhance Availability of MIPLYFFA® for Niemann-Pick Disease Type C Patients - Quiver Quantitative
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) - The Manila Times
New deal expands access to a vital Niemann-Pick C treatment beyond Europe - Stock Titan
How Zevra Therapeutics Inc. (ZVRA) Affects Rotational Strategy Timing - Stock Traders Daily
Can Zevra Therapeutics Stock Hold Up When Markets Turn? - Trefis
Can Zevra Therapeutics Inc. stock double in next 5 years2025 Institutional Moves & Technical Pattern Recognition Alerts - Bölüm Sonu Canavarı
Profit Review: How institutional buying supports Zevra Therapeutics Inc. stockJuly 2025 Trends & Long-Term Growth Stock Strategies - Улправда
Analysts’ Top Healthcare Picks: Zevra Therapeutics (ZVRA), Novan (NOVN) - The Globe and Mail
Discipline and Rules-Based Execution in ZVRA Response - Stock Traders Daily
Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? - Yahoo Finance
Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback? - Yahoo Finance
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics (ZVRA) director files report showing no holdings - Stock Titan
Schroder Investment Management Group Acquires New Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLC - MarketBeat
Zevra Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
How Zevra Therapeutics Inc. stock performs after earningsPortfolio Value Report & Expert Approved Momentum Ideas - Newser
Behavioral Patterns of ZVRA and Institutional Flows - Stock Traders Daily
Does Zevra Therapeutics’ (ZVRA) Board Turnover Subtly Recast Its Leadership and Capital Allocation Narrative? - simplywall.st
Why Zevra Therapeutics Inc. stock is favored by top institutionsDollar Strength & Stepwise Entry and Exit Trade Signals - Newser
Legal & General Group Plc Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics (ZVRA): Evaluating Valuation Following High-Profile Board Appointment and CFO Transition - simplywall.st
Zevra Therapeutics, Inc. Announces Director and Committee Changes, Effective as of December 2, 2025 - marketscreener.com
Zevra Therapeutics appoints Alicia Secor to board of directors; announces retirement of Wendy Dixon - marketscreener.com
Zevra Therapeutics Appoints Alicia Secor to Board - TipRanks
ZVRA FinancialsIncome Statement - Quiver Quantitative
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD - The Manila Times
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors, Announces Retirement of Wendy Dixon - Quiver Quantitative
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zevra Therapeutics Inc-Aktie (ZVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McFarlane Neil F. | President and CEO |
Oct 10 '25 |
Sale |
10.82 |
19,500 |
210,908 |
222,016 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):